Join the Praluent group to help and get support from people like you.
Praluent News
Praluent (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent® ...
FDA Approves Praluent (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization
PARIS and TARRYTOWN, NY – April 26, 2019 – The U.S. Food and Drug Administration (FDA) has approved Praluent (alirocumab) to reduce the risk of heart attack, stroke, and unstable angina requiring hos...
Sanofi and Regeneron Offer Praluent (alirocumab) at a New Reduced U.S. List Price
BRIDGEWATER, N.J. and TARRYTOWN, N.Y., Feb. 11, 2019 /PRNewswire/ – Praluent (alirocumab) will be made available at a new reduced U.S. list price of $5,850 annually, a 60% reduction from the...
Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent (alirocumab) Injection
BRIDGEWATER, N.J. and TARRYTOWN, N.Y., April 25, 2017 /PRNewswire/ – Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the...
FDA Approves Praluent (alirocumab) to Treat Certain Patients with High Cholesterol
July 24, 2015 – The U.S. Food and Drug Administration today approved Praluent (alirocumab) injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
High Cholesterol - Familial Heterozygous, Cardiovascular Risk Reduction, High Cholesterol, High Cholesterol - Familial Homozygous